Quest Diagnostics — 2026Q2 Earnings Review

NYSE: DGX  | Clean beat-and-raise with genuine organic reacceleration: revenue +10.2% YoY (organic +10.0%, the highest of the 12-quarter window) and adjusted EPS +19.1% YoY (a two-year high), guidance raised for the second straight quarter -- but the raise implies H2 deceleration as Corewell/Fresenius comps lap and a $0.10 one-time tax item does not repeat.

Quest Diagnostics reported 2026Q2 on July 23, 2026 (before market open) and delivered a clean, broad-based beat -- the 12th straight quarterly adjusted-EPS beat (100% in both L12Q and L4Q windows). Net revenue of $3,043M beat the ~$2,979M Zacks-derived consensus by +2.15% and grew +10.2% YoY (accelerating from +9.2% in Q1). Adjusted diluted EPS of $3.12 beat the $2.81 consensus by +11.0% and grew +19.1% YoY -- the best print in the entire 12-quarter window and the two largest beats on record came in the last two quarters (Q1'26 +5.5%, Q2'26 +11.0%), so beat magnitude is accelerating, not fading. About half the EPS upside was a one-time $0.10/share tax-contingency resolution; ex that item, adjusted EPS still grew +15.3% and still would have cleared consensus by roughly 7-8%. Critically, the Daloopa-disclosed organic revenue growth line (stripping out the Corewell Health/Fresenius Medical Care partner volumes) climbed to 10.0%, the highest of the 12-quarter window -- underlying organic demand is genuinely reaccelerating, not just riding partner M&A.

New guidance: management raised full-year 2026 guidance for the second consecutive quarter -- revenue to $11.95B-$12.05B (from $11.78B-$11.90B) and adjusted diluted EPS to $11.05-$11.25 (from $10.63-$10.83) -- and the raise was larger than the Q2 beat alone would mechanically require. But back-solving the implied H2 growth rate shows guidance embeds a second-half deceleration: ~7.8% revenue growth and ~10.2% adjusted EPS growth implied for H2, versus the ~9.7%/~16.4% actually delivered in H1 -- as Corewell/Fresenius comps lap in Q4, the 30bp ACA headwind persists, fuel costs run at the high end of range, and Project Nova spend is now 70%-weighted to H2 (up from 60% at Q1).

Tone: management moved from Q1's "solid, unchallenged raise" to a "bigger raise, more scrutinized, more explicitly defended" posture -- three separate analysts pressed on the H2 margin bridge this quarter (versus zero pushback in Q1), and CFO Sam Samad responded with a granular, numbered walk (Nova ~20bps, Corewell/Fresenius mix ~30bps, deferred-comp mark-to-market ~20bps = 70bps of Q2 headwind). A new risk topic emerged that did not exist at Q1: hospital bad debt, prompted by a peer hospital operator's bad-debt preannouncement -- management's response was proactive and detailed (patient concessions ~5% of revenue, no deterioration).

Contradictions: two internally-inconsistent statement pairs were identified on/across the calls -- (1) Jim Davis gave two different PAMA data-collection closing dates (July 30 vs. July 31) and two different CMS report-out windows within the same Q2'26 call; (2) the Corewell Co-Lab margin-ramp trajectory guided to "low teens by 2027" on the Q4'25 call is now described as "no meaningful change" but only reaching "low-single to mid-single digits" on the Q2'26 call -- low-teens and mid-single-digits cannot both be the same unchanged plan. See the Contradictions section below.

Upcoming catalysts: the PAMA CMS data-collection report (due late Sept/early Oct 2026, new Medicare rates if any effective Jan 2027) and RESULTS Act progress are the dominant policy swing factors; sell-side already raised price targets into a $232-$265 range post-print on reduced perceived PAMA tail-risk. Haystack MRD's MolDx Medicare Advantage decision is expected 2H26, and the Corewell Health Diagnostic Lab of Michigan JV facility targets a Q1 2027 launch.

DGX does not disclose a standalone EBITDA line; Adjusted Operating Income/Margin is management's own primary non-GAAP profitability metric, used here in its place. Gross profit is derived (Net Revenue − Cost of Services), both individually Daloopa-cited. >97% of revenue sits in the Diagnostic Information Services (DIS) segment. "Organic revenue growth" is a Daloopa series only populated from 2024Q3 onward.

Metric	23Q3	23Q4	24Q1	24Q2	24Q3	24Q4	25Q1	25Q2	25Q3	25Q4	26Q1	26Q2
Net revenue ($M)	2,295	2,288	2,366	2,397	2,488	2,621	2,652	2,761	2,816	2,806	2,895	3,043
Net revenue YoY	n/a	n/a	n/a	n/a	+8.4%	+14.6%	+12.1%	+15.2%	+13.2%	+7.1%	+9.2%	+10.2%
Requisition volume YoY	-0.5%	+1.9%	+1.6%	+1.1%	+5.5%	+13.9%	+12.4%	+16.3%	+12.5%	+8.5%	+10.9%	+13.1%
Revenue/requisition YoY	-7.2%	-3.5%	+0.1%	+1.6%	+3.3%	+0.2%	+0.3%	-0.4%	+0.8%	-0.1%	-1.3%	-2.8%
Organic revenue growth (total)	—	—	—	—	4.2%	5.0%	2.5%	5.2%	6.8%	6.4%	9.0%	10.0%
Gross margin	32.85%	32.17%	32.59%	33.54%	32.60%	32.74%	32.54%	34.15%	33.70%	32.43%	32.54%	33.75%
Gross margin YoY (bps)	n/a	n/a	n/a	n/a	-26	+57	-5	+61	+110	-31	-0	-40
Adj. operating income ($M)	380	338	349	398	385	409	406	466	458	429	447	502
Adj. operating margin	16.56%	14.77%	14.75%	16.60%	15.47%	15.60%	15.31%	16.88%	16.26%	15.29%	15.44%	16.50%
Adj. op. margin YoY (bps)	n/a	n/a	n/a	n/a	-108	+83	+56	+27	+79	-32	+13	-38
Adjusted diluted EPS ($)	2.22	2.15	2.04	2.35	2.30	2.23	2.21	2.62	2.60	2.42	2.50	3.12
Adj. diluted EPS YoY	n/a	n/a	n/a	n/a	+3.6%	+3.7%	+8.3%	+11.5%	+13.0%	+8.5%	+13.1%	+19.1%
GAAP diluted EPS ($)	1.96	1.70	1.72	2.03	1.99	1.95	1.94	2.47	2.16	2.18	2.24	2.84
GAAP diluted EPS YoY	n/a	n/a	n/a	n/a	+1.5%	+14.7%	+12.8%	+21.7%	+8.5%	+11.8%	+15.5%	+15.0%

Read-through: both organic revenue growth and reported revenue growth are now running at their highest levels of the 12-quarter window (10.0% / 10.2%), up from ~4-6% organic through most of 2025 -- the acceleration is not just an acquisition/partner-volume story. Adjusted operating margin compressed -38bps YoY on a well-explained, temporary mix of Project Nova spend (~20bps) and Corewell/Fresenius ramp dilution (~30bps) plus deferred-comp mark-to-market (~20bps), which management says laps by Q4 2026.

Data sourced from Daloopa (company_id 542). Q2 2026 driver color (Corewell/Fresenius volume contribution, margin bridge) is transcript-sourced from the Quest Diagnostics Q2 2026 earnings call (2026-07-23).

Quest beat consensus on both revenue and adjusted EPS in Q2 2026, and the beat was not solely a tax artifact -- excluding a one-time $0.10/share tax-contingency resolution, adjusted EPS still would have cleared consensus by roughly 7-8%. No consensus dataset was available this session (Bloomberg/Visible Alpha offline); consensus figures are triangulated from Zacks-sourced press coverage, flagged as directionally solid but not vendor-audited to the decimal.

Metric	Q3'24	Q4'24	Q1'25	Q2'25	Q3'25	Q4'25	Q1'26	Q2'26 (this qtr)
Adj. EPS surprise	+1.8%	+1.8%	+2.8%	+1.9%	+3.6%	+2.5%	+5.5%	+11.0%
Revenue surprise	~+2.6%	n/a	+1.5%	n/a	+3.45%	+2.18%	n/a	+2.15%

Pattern: consistent beater, and the beats are getting bigger, not smaller. Quest has not missed adjusted EPS consensus in any of the last 12 tracked quarters. The last two prints (Q1'26 +5.5%, Q2'26 +11.0%) are the two largest beats in the entire window -- roughly triple the average surprise of the four quarters before that. Revenue also beat consensus in every quarter for which a figure could be sourced this session, so the pattern is not an EPS-only cost-cutting artifact.

Actuals — Daloopa (company_id 542; Adjusted Diluted EPS and Net Revenues series, cited per-quarter above). Consensus/surprise — Zacks-sourced press coverage via web search (no Bloomberg/Visible Alpha consensus feed connected this session, flagged per company_context.md).

Quest guides annually only (full-year revenue, EPS, cash flow, capex) -- it does not issue quarterly (FQ+1) guidance. No consensus dataset was available this session (no Visible Alpha/Bloomberg connection, no consensus snapshot on file for DGX); every "vs Consensus" cell below reads "n/a -- no consensus feed connected," not a fabricated figure.

Waterfall — FY2026 guidance vintages, revenue & adjusted EPS midpoints

Reading the trajectory: each vintage raised both ends, and the rate of raise accelerated -- revenue growth midpoint moved +0.8pts initial-to-Q1, then +1.4pts Q1-to-Q2; adjusted EPS growth midpoint moved +1.3pts then +4.3pts. The Q2 raise was larger than the Q2 beat alone would mechanically require, indicating management is pulling forward some H2 confidence too.

FY2026 guidance vs. prior and consensus

Reported trend vs. what the raise implies for H2 2026

Quest does not disclose a Q3/Q4 split within H2, so no further quarterly decomposition is offered. Management explicitly flagged that Q4 will see the biggest step-down as Corewell/Fresenius lap and the ACA headwind is felt more fully -- a straight-line H2 split understates Q3 and overstates Q4. Does guidance lead or lag the reported trend? It lags, deliberately -- reported growth accelerated Q1→Q2 on both lines, yet the new full-year guide implies H2 growth below the H1 pace, consistent with a conservative-guide pattern (banking the H1 beat) rather than extrapolating it forward. No FY2027 guidance exists yet; Quest's practice is to issue next-year guidance at the Q4 call.

Management tone: Q1 2026 vs. Q2 2026

Net read: tone moved from "solid, on-track, unchallenged raise" (Q1) to "bigger raise, more scrutinized, more explicitly defended" (Q2) — a business executing better than plan, facing a Street testing whether the embedded H2 deceleration is conservatism or an early signal of mix/cost pressure building.

Accel = current-quarter YoY% minus prior-quarter YoY%, in basis points. Positive = accelerating growth; negative = decelerating growth.

Plain-English assessment: DGX's growth engine has shifted sources twice in eight quarters without ever going organic-only: 2024 was M&A-fueled (LifeLabs + outreach labs), 2025 handed the baton to the Corewell/Fresenius Co-Lab partnerships, which reaccelerated both lines through mid-2025 then mechanically decelerated in Q4'25 as those deals lapped. Heading into Q2 2026, the trend turned back up on both lines simultaneously — revenue accelerating for two straight quarters (+210bps, then +105bps) and EPS accelerating even more sharply (+460bps, then +596bps to a two-year high of 19.08%) — with management citing broad-based organic demand (double-digit growth in advanced cardiometabolic, brain health/AD-detect, Haystack MRD gaining state approvals) on top of still-scaling Corewell/Fresenius volumes. Net: this inflection looks like genuine reacceleration, not a sugar-high — though the Q2'26 EPS beat is flattered by a $0.10 tax item, and the FY26 guide raise implies H2 decelerates modestly as Corewell/Fresenius comps lap again in Q4'26.

The near-term catalyst stack is policy-dominated: the PAMA CMS data-collection outcome and RESULTS Act progress are the swing factors the Street is watching, alongside Haystack MRD's pending MolDx Medicare Advantage decision — none of which are baked into FY26 guidance. No Carbon Arc/Snowflake/Visible Alpha alt-data connection was available this session; DGX is a low-alt-data-coverage, B2B/payer-driven business, so the alt-data column is marked N/A rather than fabricated.

Catalyst	Timing	Management commentary	Street / consensus view
PAMA CLFS data-collection outcome	Data collection closed Jul 30-31, 2026; CMS report expected late Sept/early Oct 2026; new rates (if any) effective Jan 1, 2027	Davis: 3 possible outcomes — CMS proceeds with new rates, RESULTS Act passes, or another delay (6 to date); guidance embeds no specific outcome	Treated as a 2027 tail-risk item; Congress already granted a 1-year moratorium through Dec 2026; Barclays/BofA/Mizuho/UBS/Jefferies raised PTs into $232-$265 post-print
RESULTS Act	No scheduled vote; needs committee markup, CBO score, CMS technical assessment	Davis: "115+ cosponsors, 60+ patient/consumer organizations, one successful House hearing"; Quest lobbies for passage regardless of the CMS-track outcome	Multi-quarter overhang/optionality item, not near-term-priced
Haystack MRD — Medicare Advantage (MolDx) decision	Expected 2H 2026	NY State approval opens all 50 states; Flatiron/OncoEMR pilot rolling to ~4,700 oncology clinicians; investment paced "commensurate with reimbursement"	Framed as approaching a ~$20B cancer-recurrence market; ~70% of Haystack volume already covered as of 2025; treated as 2027+ P&L driver
Diagnostic Lab of Michigan (Corewell JV) facility launch	Facility (100,000 sq ft) targeted Q1 2027; JV entity already legally formed Jan 2026	Samad: Corewell ~$250M FY26 revenue contribution "largely as expected," margin low-single to mid-single digits through the year	Street expects the ~30bps op-margin dilution to fade as the relationship laps in Q4'26 and the JV scales into 2027
ACA marketplace subsidy expiration	Ongoing through 2H 2026	30bps full-year revenue headwind reaffirmed; enrollment down >20% but sicker-patient mix keeps exchange book "flattish"	Street watching for the headwind to widen in 2H; management held the line at 30bps
Hospital Co-Lab / outreach M&A pipeline	Ongoing; latest Co-Lab agreement closed with a CA regional health system in Q2'26	Davis: "funnel of opportunities looks good"; FY26 guidance excludes any prospective M&A	Any signed deal is incremental upside optionality, not a guidance risk
Elevance Alzheimer's blood-biomarker coverage precedent	pTau-217 already covered; amyloid (AB-4240) not yet	Davis: Elevance "one of, if not the first major payer" to reimburse; Alzheimer's testing book growing "high, high double digits" (undisclosed size)	Precedent-setting decision the Street watches for broader commercial-payer read-through; not yet guided to
Q3 weather / Project Nova cost-timing	Q3 2026 (weather); 2H26 (Nova spend)	Nova now ~70% H2-weighted (vs 60% prior); fuel costs at high end of range (~$10M); Q3 weather an explicit "wildcard"	Analyst-pressed margin-bridge caveat, not a Street-consensus catalyst per se

Sources: Quest Diagnostics Q2 2026 earnings call transcript (2026-07-23); sell-side/trade-press coverage (ACLA, Bass Berry & Sims, MedTech Dive, GuruFocus, ainvest.com, Quest Diagnostics IR, Becker's Hospital Review). No BlueMatrix/AlphaSense/Carbon Arc/Snowflake connectivity this session.

13 analyst questions from the Q2 2026 call (Jim Davis, CEO; Sam Samad, CFO). Scorecard: 9 Well Answered / 4 Deflected or Avoided. All four deflections involve either a specific number the analyst asked for and management chose not to disclose, or a granular trend comparison management answered at a higher level of generality.

Analyst / topic	Management response (summary)	Badge
Erin Wilson Wright (Morgan Stanley) — hospital pipeline / Co-Lab bad debt	Broke hospital book into reference vs. Co-Lab ex-Corewell (both mid-single-digit growth); no bad debt concern flagged; new CA Co-Lab deal cited.	Well Answered
Lisa Gill (JPMorgan) — 30bp ACA headwind update	Guidance unchanged at ~30bps; granular volume/mix math shown (exchange volume -8%, tests-per-req +6%, net revenue flattish).	Well Answered
Michael Cherny / Meghan Holtz (Leerink) — H2 margin bridge	Fully quantified Q2's 70bps headwind (Nova ~20bp, Corewell/Fresenius mix ~30bp, deferred-comp ~20bp) and H2 assumptions.	Well Answered
Michael Ryskin (BofA) — Corewell guide / pricing deceleration vs. Q1	Corewell reaffirmed at $250M; on pricing, gave only the standing company-wide answer, sidestepping the specific Q1-vs-Q2 sequential-deceleration math asked for.	Deflected
Ann Hynes (Mizuho) — bad debt sizing after peer preannouncement	Reaffirmed no deterioration; patient concessions ~5% of revenue, "slightly improved" — but never isolated or quantified bad debt itself or the guidance-embedding ask.	Deflected
Anna Kruszenski (Barclays, for Luke Sergott) — DSOs up YoY/sequentially	Two clean reasons: a deposit-timing technicality and a genuine mix shift to higher-DSO client-bill/consumer business.	Well Answered
Noah Kava (Jefferies, for Tycho Peterson) — PAMA outlook	Comprehensive 3-scenario framework, quantified history (original $2.5B savings estimate vs. $4B actual in 3 years).	Well Answered
Elizabeth Anderson (Evercore ISI) — hospital deal pipeline / ACA linkage	Detailed the three engagement models and selectivity criterion; the specific ACA-causality thread addressed only implicitly.	Well Answered
Kevin Caliendo (UBS) — rev/req ex-Corewell/Fresenius acceleration	Test-per-req identified as primary driver (up from 3.5-4.0x pre-COVID to "almost north of 4.5"); consumer + esoteric mix as supporting legs.	Well Answered
Piper Sandler (for David Westenberg) — Haystack MRD / Guardant "Shield" partner volumes	Haystack answer strong and specific (NY approval, Flatiron rollout); explicitly declined to discuss the partner's draw-fee volumes.	Deflected
Patrick Donnelly (Citi) — H2 utilization backdrop / pricing tone	Segment-by-segment utilization confirmed strong; real-time data point (first 3 weeks of Q3 consistent with Q2); discrete H2 swing factors listed.	Well Answered
Jay Lewis (Baird) — Elevance Alzheimer's biomarker sizing	Confirmed pTau-217 coverage, but explicitly declined to size the book: "we're not going to provide today the absolute size of that business."	Deflected
Jack Meehan (Oppenheimer) — PAMA/RESULTS Act latest thinking	Repeated the 3-scenario framework with added mechanical detail (rate-cut cap, effective-date sequencing) — no new information withheld.	Well Answered

Deflection summary: (1) BofA's pricing sequential-deceleration question got the standing flattish-pricing narrative rather than the specific Q1-vs-Q2 math; (2) Mizuho's bad-debt-as-%-of-revenue ask got a patient-concessions proxy instead of an isolated figure; (3) Piper Sandler's Guardant/Shield partner-volume question was explicitly declined; (4) Baird's Alzheimer's book-size ask got only a directional growth rate. Common thread: all four involve a specific number management chose not to disclose, or a granular comparison answered at a higher level of generality.

Scope reviewed: all 8 staged transcripts (Q3 2024 → Q2 2026) plus internal notes. Two contradictions were found; both involve the just-reported Q2 2026 call.

Source	Quote
Q2'26 call — response to Noah Kava (Jefferies)	"...there's a current data collection process going on by CMS and that data collection process ends on July 30. We expect to hear something, let's say, late September, early August."
Q2'26 call — response to Jack Meehan (later, same call)	"...It ends on July 31. We have submitted, by the way. We would expect CMS to report out on that in the September -- late September, early October time frame."

Source	Quote
Q4'25 call (Jim Davis, on Corewell/Fresenius margin ramp)	"On Corewell, we said it is a $250-ish million book of business for us in 2026. And we said that would start out at low single-digit margin rate. As we get into 2027, we expect that to be in the low teens."
Q2'26 call (Sam Samad, follow-up on Corewell)	"I would say the margin rate, which we had set is going to be in the low single digits, improving to mid-single digits, is still largely playing out as we expected... really no meaningful change in terms of our expectations from Corewell."

Reviewed and reconciled, not counted as contradictions: the ACA/exchange 30bp headwind assumption (repeated identically Q1'26 and Q2'26); RESULTS Act cosponsor counts (65 → 80 → 115, a monotonic increase, consistent with a bill gaining support); Corewell/Fresenius total revenue-impact sizing (~$250M + ~$80-100M, consistent Q1'26 and Q2'26); bad debt/patient-concessions commentary ("no deterioration" consistent Q3'25 and Q2'26); hospital reference-business growth (3% in Q1'26 to "mid-single digits" in Q2'26 — an acceleration, not a conflict).

Macro commentary

Theme	Commentary	Read-through
ACA exchange subsidy expiration	"Enrollment is down north of 20%... But that's not translating into our business" — Jim Davis. Adverse-selection mechanism: exchange req volume -8%, tests-per-req +6%, net revenue "flattish."	30bps headwind held, not worsened this quarter; could deteriorate further in 2H per management's own caveat.
Hospital-sector bad debt (sector-wide, not DGX-specific)	Analyst: "one of the big hospital companies preannounced and most of that was just an increase in bad debt." Samad: no meaningful bad-debt change at Quest; patient concessions ~5% of revenue, slightly improved YoY.	Positive divergence — a hospital operator's bad-debt deterioration is a patient-pay/point-of-care risk not shared by lab-testing intermediaries like Quest.
Input cost inflation — fuel/fleet, wages	Fuel costs at high end of range (~$10M for the year); wage inflation cited as a partial offset to organic operating-leverage gains.	Modest, real 2H26 margin headwind layered on top of Project Nova and deferred-comp mark-to-market.
PAMA / lab reimbursement policy (industry-wide)	CMS private-payer data collection closes Jul 30-31; only ~1% of ~10,000 eligible labs submitted last cycle. RESULTS Act (115+ cosponsors) is the industry's preferred fix.	Industry-wide regulatory catalyst/risk relevant to peer labs (e.g., Labcorp), not DGX-specific.

Companies mentioned

Company	Relationship	Read-through
Corewell Health	Hospital Co-Lab partner (Michigan)	Positive/on-track — $250M FY26 impact "largely as expected"; scaling to a JV in early 2027; dilutive to margin near-term (~30bps) but improving and laps in Q4.
Fresenius Medical Care	Kidney-testing collaboration partner (dialysis)	Positive — book of business up ~$100M YoY with margin improving quarter by quarter, tied to ~36M Americans with chronic kidney disease.
Unnamed large hospital operator	Sector peer, not a DGX partner	Negative for that operator (bad-debt preannouncement) but explicitly not shared by Quest — a divergence positive for DGX.
Elevance Health	Major health plan/payer	Positive for Alzheimer's testing volumes (first-mover pTau-217 coverage) but the 4-state access win from Q1 2025 laps in 2H26 — a growth-rate deceleration read-through.
CMS / Medicare, Medicare Advantage	Regulator / payer	Policy overhang for the whole clinical-lab industry (DGX, Labcorp); 2027 rate-setting catalyst, unresolved this quarter.
Flatiron Health / American Oncology Network	Oncology EMR / molecular-profiling integration partners	Positive distribution read-through for Haystack MRD — ~4,700 community-oncology clinicians reachable via existing EMR workflow.
Guardant Health ("Shield")	Liquid-biopsy competitor; DGX performs the blood draw (fee-for-service)	Neutral-to-modestly positive — draw-fee income regardless of test-maker, but underscores DGX's coopetition role vs. assay ownership in liquid biopsy.

Data sourced from Daloopa (company_id 542), the Quest Diagnostics 2026Q2 earnings call transcript (2026-07-23, BMO), and Zacks-sourced/web-aggregated consensus and press coverage (last resort where Bloomberg/Visible Alpha were offline this run, flagged inline). Prepared July 27, 2026 for the 2026Q2 print reported July 23, 2026 (BMO).